View clinical trials related to Parkinson Disease 6, Early-Onset.
Filter by:The purpose of this study is to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 vaccination in patients with early stages of Parkinson's disease.
Background: - Parkinson s disease is a disease of the nervous system that affects movement. People usually get it in their 70s or 80s. Early onset Parkinson s disease (EOPD) begins before the age of 50. Researchers think EOPD may be caused by a mutation in a gene. They want to study the genetic causes so they can find therapies for this disease. Objective: - To better understand the genetic causes of EOPD. Eligibility: - Adults ages 18 80 with a history of EOPD. Their family members, who do not have Parkinson s disease, can join as controls. - Healthy volunteers ages 18 80. Design: - Participants with EOPD and their relatives will be screened with a review of medical records. Healthy volunteers will have medical history, physical exam, and blood drawn. - Relatives may send blood samples to NIH to test for mutations in genes that are linked to Parkinson s disease. They may have a physical exam. - Participants may be asked to return to clinic for another visit that can last up to 2 hours. - During this visit, participants will have blood taken from a vein in the arm via a needle stick. - Participants may give a sample of their skin. The skin on the arm or leg will be numbed and a small skin punch biopsy will be taken with a special needle. - Some cells from the blood or skin sample may be grown in a lab to establish cell lines. The cells may also potentially be genetically modified to make stem cells. - Researchers may perform genetic analysis on the samples to compare them to EOPD patient samples.